Treatment of Moderate to Severe Refractory Crohn's Disease

Exclusion Criteria

• •1. Prior organ transplant, or allogeneic bone marrow, peripheral blood, or cord blood stem cell transplant. Note: Blood transfusion are not exclusionary if it occurred ≥ 3 years (- 3 months) of TRX103 infusion.
• •2. Received another investigational agent or therapy, within 28 days of planned TRX103 infusion (or 5 half-lives, whichever is longer) and/or have not recovered from treatment related toxicities.
• •3. Received any approved treatment for CD within the designated washout period (including off-label use of approved therapies) as per the protocol.
• •4. Strictures, active fistulae (including perianal), or abscess by computed tomography (CT) or magnetic resonance enterography (MRE) or Endoscopy within 6 months of Screening.
• •5. Positive serology for HIV.
• •6. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.
• •7. Hepatitis C virus (HCV RNA detectable in any subject with anti-HCV antibodies).
• •8. Subject with active or chronic recurring infections or untreated latent Tuberculosis (TB).
• •9. Current diagnosis of ulcerative colitis (UC), indeterminate colitis or CD isolated to colon only (the colitis must be related to CD and inclusive of ileal with or without colonic involvement).
• •10. Subjects with the following known complications of Crohn's Disease
• •* active diverticulitis,
• •* active fistulae or abscess,
• •* abscess (abdominal or perianal) - abscess with no evidence of pus when pressed upon are permitted,
• •* impassable fibrotic strictures - Patients with strictures passable by dilation are permitted,
• •* symptomatic bowel strictures - must be confirmed via endoscopy and/or radiologically,
• •* fulminant colitis,
• •* toxic megacolon,
• •* ostomy or ileoanal pouch - previous temporary ostomy pouch, followed by a reversal is permitted,
• •* diagnosed with short gut or short bowel syndrome,
• •* or any other manifestation that might require surgery while enrolled in the study.
• •11. Subject with surgical bowel resection within the past 3 months prior to Screening, or a history of \> 2 bowel resections. Note: Surgery for temporary use of an ostomy bag or reconnection of the gut post colostomy use is not considered exclusionary, nor considered as part of the surgical resection if during the reconnection removal of tissue is required to facilitate reattachment.
• •12. Subjects that are pregnant, breast feeding, or aim to become pregnant during the 12 month study period. (Subjects, males and females, must agree to use a highly effective method of contraception).
• •13. Screening laboratory and other analyses show any of the following abnormal results:
• •* Serum aspartate transaminase or alanine transaminase \> 3.0 × upper limit of normal;
• •* Total white blood cell count \< 2,000/μL;
• •* Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula or by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \< 40 mL/min/1.73 m2;
• •* Hemoglobin \< 8 g/dL;
• •* Bilirubin ≥ 2 x ULN;
• •* Platelet count \< 100,000/μL;
• •* Absolute neutrophil count \< 1,200/μL;
• •* Absolute lymphocytes count \< 750/μL.
• •14. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.
• •15. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results, which, in the Investigator's opinion:
• •* places the subject at increased risk during participation in the study, and/or;
• •* interferes with the subject's capacity to provide informed consent and their participation in the study, and/or;
• •* interferes with the interpretation of the results.